Hematology Clinic
The Pediatric Hematology Clinic provides comprehensive care for children and adolescents who have noncancerous blood conditions, including anemias; abnormalities of red or white blood cells and platelets; and inherited disorders, such as sickle cell disease and hemophilia. For blood cancer care, please see our Pediatric Cancer Program.
Depending on the disease, our clinic offers treatments ranging from medications and immunotherapies to complex transfusions and bone marrow transplants. Being based at a hospital that's active in research on blood disorders, we're able to access new treatments as soon as they're proven safe and effective.
We understand that the diagnosis and treatment of a blood disorder can be difficult for young patients, both physically and emotionally. For that reason, we're dedicated to giving our patients not only the highest quality medical care but also to offering a range of support services to make the journey smoother.
Our team includes doctors who are experts in pediatric blood diseases as well as nurse specialists, psychologists, social workers and child life specialists. When a patient is eligible for a transplant, we collaborate with the Pediatric Blood & Marrow Transplant Clinic. Our goals are to ensure the best possible outcomes and offer every child an improved and lasting quality of life.
Our locations (5)
Our team
-
Shreya Agarwal
MD
Pediatric hematologist -
Maria I. Castellanos
MD
Pediatric hematologist-oncologist -
Robert Ward Hagar
MD
Internist -
Caroline Hastings
MD
Hematologist-oncologist and neuro-oncologist -
Michelle L. Hermiston
MD, PhD
Pediatric hematologist-oncologist -
James Huang
MD
Pediatric hematologist -
Anya Levinson
MD
Pediatric hematologist-oncologist -
Alison Matsunaga
MD
Pediatric hematologist-oncologist -
Jennifer Michlitsch
MD
Pediatric hematologist-oncologist -
Robert Raphael
MD
Pediatric hematologist-oncologist -
Elizabeth Robbins
MD
Pediatric hematologist-oncologist -
Kristin A. Shimano
MD
Pediatric hematologist-oncologist -
Sylvia Singer
MD
Pediatric hematologist-oncologist -
Elliott Vichinsky
MD
Pediatric hematologist-oncologist -
Beth Apsel Winger
MD, PhD
Pediatric hematologist-oncologist -
Mary B. Lesh
PNP, CNS, MSN
Pediatric nurse practitioner -
Laura Quill
PNP, MSN
Pediatric nurse practitioner -
Marsha J. Treadwell
PhD
Psychologist -
Katrina Unpingco
FNP, MSN
Nurse practitioner
Awards & recognition
-
Ranked among the nation's best in 10 specialties
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
- Completed medical forms that we will mail to you ahead of time
Related clinics (7)
Blood & Marrow Transplant (BMT) Clinic
Support services
Clinical trials
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm
Recruiting
More about this studyStudy Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patien...
Response defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target...
Recruiting
More about this studyInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyA Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Dia...
Will be assessed in SR-High patients and SR-Avg B-ALL patients who are negative for MRD by flow cytometry but have detectable or indeterminate MRD as measured by high throughput sequencing (HTS) at end of induction (EOI), and pati...
Recruiting
More about this studyA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...
Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...
Recruiting
More about this studyA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...
Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...
Recruiting
More about this studyStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or ...
For patients assigned to arms A and B, the investigators will separately estimate the proportion of patients who experience conjugated hyperbilirubinemia > 3mg/dL during induction chemotherapy by arm along with corresponding 95% c...
Recruiting
More about this studyStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or ...
For patients assigned to arms A and B, the investigators will separately estimate the proportion of patients who experience conjugated hyperbilirubinemia > 3mg/dL during induction chemotherapy by arm along with corresponding 95% c...
Recruiting
More about this studyOur research initiatives
Stress-free visits